Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy

Nadine Sommer; Ahlima Roumane; Weiping Han; Mirela Delibegović; Justin J. Rochford; George D. Mcilroy

doi:10.1016/j.omtm.2022.09.014

Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy

Nadine Sommer, Ahlima Roumane, Weiping Han, Mirela Delibegović, Justin J. Rochford, George D. Mcilroy^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

4 Downloads (Pure)

Abstract

Congenital generalised lipodystrophy type 2 is a serious multisystem disorder with limited treatment options. It is caused by mutations affecting the BSCL2 gene, which encodes the protein seipin. Patients with congenital generalised lipodystrophy type 2 lack both metabolic and mechanical adipose tissue and develop severe metabolic complications including hepatic steatosis, lipoatrophic diabetes and cardiovascular disease. Gene therapies are becoming viable treatments, helping to alleviate inherited and acquired human disorders. We aimed to determine whether gene therapy could offer an effective form of medical intervention for lipodystrophy. We examined whether systemic adeno-associated virus delivery of human BSCL2 could reverse metabolic disease in seipin knockout mice, where white adipose tissue is absent. We reveal adeno-associated virus gene therapy targets adipose progenitor cells in vivo and substantially restores white adipose tissue development in adult seipin knockout mice. This resulted in both rapid and prolonged beneficial effects to metabolic health in this pre-clinical mouse model of congenital generalised lipodystrophy type 2. Hyperglycaemia was normalised within two weeks post-treatment, together with normalisation of severe insulin resistance. We propose that gene therapy offers great potential as a therapeutic strategy to correct multiple metabolic complications in patients with congenital lipodystrophy.

Original language	English
Pages (from-to)	206-216
Number of pages	11
Journal	Molecular Therapy - Methods & Clinical Development
Volume	27
Early online date	19 Oct 2022
DOIs	https://doi.org/10.1016/j.omtm.2022.09.014
Publication status	Published - 8 Dec 2022

Bibliographical note

The authors are extremely grateful to Dr Donna MacCallum (University of Aberdeen) for assistance with AAV vector i.v. tail vein injections and Pat Bain (University of Aberdeen) for design and generation of the graphical abstract. The authors would also like to thank the staff at the University of Aberdeen’s Microscopy and Histology Core Facility and the Medical Research Facility for support with animal breeding and maintenance. This research was supported by funding from the EFSD/Lilly Young Investigator Research Award Programme, Wellcome Trust ISSF Fellowship Support Fund, and Diabetes UK RD Lawrence Fellowship (21/0006280) awarded to G.D.M. and Diabetes UK (18/0005884) awarded to J.J.R.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.omtm.2022.09.014Licence: CC BY

Sommer_etal_MT_Gene_Therapy_Restores_VOR
https://creativecommons.org/licenses/by/4.0/
Final published version, 1.46 MBLicence: CC BY

https://www.sciencedirect.com/science/article/pii/S2329050122001395Licence: CC BY

Microscopy and Histology
Debbie Wilkinson (Manager) & Gillian Milne (Manager)
Medical Sciences
Research Facilities: Facility

Cite this

@article{9bac7a0716024a1e8da8309dc8326e81,

title = "Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy",

abstract = "Congenital generalised lipodystrophy type 2 is a serious multisystem disorder with limited treatment options. It is caused by mutations affecting the BSCL2 gene, which encodes the protein seipin. Patients with congenital generalised lipodystrophy type 2 lack both metabolic and mechanical adipose tissue and develop severe metabolic complications including hepatic steatosis, lipoatrophic diabetes and cardiovascular disease. Gene therapies are becoming viable treatments, helping to alleviate inherited and acquired human disorders. We aimed to determine whether gene therapy could offer an effective form of medical intervention for lipodystrophy. We examined whether systemic adeno-associated virus delivery of human BSCL2 could reverse metabolic disease in seipin knockout mice, where white adipose tissue is absent. We reveal adeno-associated virus gene therapy targets adipose progenitor cells in vivo and substantially restores white adipose tissue development in adult seipin knockout mice. This resulted in both rapid and prolonged beneficial effects to metabolic health in this pre-clinical mouse model of congenital generalised lipodystrophy type 2. Hyperglycaemia was normalised within two weeks post-treatment, together with normalisation of severe insulin resistance. We propose that gene therapy offers great potential as a therapeutic strategy to correct multiple metabolic complications in patients with congenital lipodystrophy.",

author = "Nadine Sommer and Ahlima Roumane and Weiping Han and Mirela Delibegovi{\'c} and Rochford, {Justin J.} and Mcilroy, {George D.}",

note = "The authors are extremely grateful to Dr Donna MacCallum (University of Aberdeen) for assistance with AAV vector i.v. tail vein injections and Pat Bain (University of Aberdeen) for design and generation of the graphical abstract. The authors would also like to thank the staff at the University of Aberdeen{\textquoteright}s Microscopy and Histology Core Facility and the Medical Research Facility for support with animal breeding and maintenance. This research was supported by funding from the EFSD/Lilly Young Investigator Research Award Programme, Wellcome Trust ISSF Fellowship Support Fund, and Diabetes UK RD Lawrence Fellowship (21/0006280) awarded to G.D.M. and Diabetes UK (18/0005884) awarded to J.J.R. ",

year = "2022",

month = dec,

day = "8",

doi = "10.1016/j.omtm.2022.09.014",

language = "English",

volume = "27",

pages = "206--216",

journal = "Molecular Therapy - Methods & Clinical Development",

issn = "2329-0501",

publisher = "Cell Press",

}

TY - JOUR

T1 - Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy

AU - Sommer, Nadine

AU - Roumane, Ahlima

AU - Han, Weiping

AU - Delibegović, Mirela

AU - Rochford, Justin J.

AU - Mcilroy, George D.

N1 - The authors are extremely grateful to Dr Donna MacCallum (University of Aberdeen) for assistance with AAV vector i.v. tail vein injections and Pat Bain (University of Aberdeen) for design and generation of the graphical abstract. The authors would also like to thank the staff at the University of Aberdeen’s Microscopy and Histology Core Facility and the Medical Research Facility for support with animal breeding and maintenance. This research was supported by funding from the EFSD/Lilly Young Investigator Research Award Programme, Wellcome Trust ISSF Fellowship Support Fund, and Diabetes UK RD Lawrence Fellowship (21/0006280) awarded to G.D.M. and Diabetes UK (18/0005884) awarded to J.J.R.

PY - 2022/12/8

Y1 - 2022/12/8

N2 - Congenital generalised lipodystrophy type 2 is a serious multisystem disorder with limited treatment options. It is caused by mutations affecting the BSCL2 gene, which encodes the protein seipin. Patients with congenital generalised lipodystrophy type 2 lack both metabolic and mechanical adipose tissue and develop severe metabolic complications including hepatic steatosis, lipoatrophic diabetes and cardiovascular disease. Gene therapies are becoming viable treatments, helping to alleviate inherited and acquired human disorders. We aimed to determine whether gene therapy could offer an effective form of medical intervention for lipodystrophy. We examined whether systemic adeno-associated virus delivery of human BSCL2 could reverse metabolic disease in seipin knockout mice, where white adipose tissue is absent. We reveal adeno-associated virus gene therapy targets adipose progenitor cells in vivo and substantially restores white adipose tissue development in adult seipin knockout mice. This resulted in both rapid and prolonged beneficial effects to metabolic health in this pre-clinical mouse model of congenital generalised lipodystrophy type 2. Hyperglycaemia was normalised within two weeks post-treatment, together with normalisation of severe insulin resistance. We propose that gene therapy offers great potential as a therapeutic strategy to correct multiple metabolic complications in patients with congenital lipodystrophy.

AB - Congenital generalised lipodystrophy type 2 is a serious multisystem disorder with limited treatment options. It is caused by mutations affecting the BSCL2 gene, which encodes the protein seipin. Patients with congenital generalised lipodystrophy type 2 lack both metabolic and mechanical adipose tissue and develop severe metabolic complications including hepatic steatosis, lipoatrophic diabetes and cardiovascular disease. Gene therapies are becoming viable treatments, helping to alleviate inherited and acquired human disorders. We aimed to determine whether gene therapy could offer an effective form of medical intervention for lipodystrophy. We examined whether systemic adeno-associated virus delivery of human BSCL2 could reverse metabolic disease in seipin knockout mice, where white adipose tissue is absent. We reveal adeno-associated virus gene therapy targets adipose progenitor cells in vivo and substantially restores white adipose tissue development in adult seipin knockout mice. This resulted in both rapid and prolonged beneficial effects to metabolic health in this pre-clinical mouse model of congenital generalised lipodystrophy type 2. Hyperglycaemia was normalised within two weeks post-treatment, together with normalisation of severe insulin resistance. We propose that gene therapy offers great potential as a therapeutic strategy to correct multiple metabolic complications in patients with congenital lipodystrophy.

U2 - 10.1016/j.omtm.2022.09.014

DO - 10.1016/j.omtm.2022.09.014

M3 - Article

C2 - 36320417

SN - 2329-0501

VL - 27

SP - 206

EP - 216

JO - Molecular Therapy - Methods & Clinical Development

JF - Molecular Therapy - Methods & Clinical Development

ER -

Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Equipment

Microscopy and Histology

Cite this